Algiax raises €3.2M Series A round
11 July 2013· Erkrath, Germany· health, pharmaceuticals, biotech, b2b, deep_hardware, drug_discovery
The capital will be used to advance the lead candidate AP-157 into clinical Phase I trials.
Investors
LeadHigh-Tech Gründerfonds
Also participating
NRW.Bank
About Algiax
Stage
Series B
Headquarters
Erkrath, Germany
Founded
2011
Team Size
6–20
Sectors
healthpharmaceuticalsbiotechb2bdeep_hardwaredrug_discovery